AllPennyStocks.com BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

Other Penny Stock Movers

This Critical Minerals Explorer Just Found Where to Look Next
This Cannabis Microcap Just Bought Its Way Into Two of Europe's Biggest Markets
BC Copper-Gold Explorer Surges 40% on Maiden Drill Visuals
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top